AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02508857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
Study NCT02508857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
Study NCT02508857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
Study NCT04391361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine, atropine, edaravone and dexmedetomidine
Description: The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
Study NCT04391361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edaravone
Description: The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
Study NCT03477123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking therapy with Exo-H2 exoskeleton
Study NCT02462252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
Study NCT02462252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: horse anti-thymocyte globulin (hATG)
Description: From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
Study NCT02462252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
Study NCT02462252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
Study NCT04354142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSpy
Description: iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
Study NCT03611491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Princess FILLER Lidocaine
Description: Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
Study NCT01524731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal Saline
Study NCT01524731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg
Study NCT01524731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg
Study NCT01034150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relief band (Somatosensory stimulation)
Description: Electrical median nerve stimulation
Study NCT01034150 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stimulation
Description: Placebo stimulation
Study NCT03870100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1222
Description: Pharmaceutical form: water injection Route of administration: subcutaneous
Study NCT03379870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic Speech Processor: Full-electric stimulation fitting
Description: Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
Study NCT00297791 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: randomized to open or laparoscopic technique
Study NCT01598948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
Study NCT02615535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-EEG feedback-assisted meditation
Description: meditation without auditory feedback regarding EEG status
Study NCT03662399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Orthotic Insoles
Study NCT00551824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
Study NCT03662399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard shoe
Description: Standard shoe
Study NCT02404337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Study NCT03584490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Talking Touchscreen
Description: The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand.
Study NCT02428088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 2 mg once daily
Study NCT02428088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4 mg once daily
Study NCT02428088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo once daily
Study NCT01958099 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Study NCT01958099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study NCT02902172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Study NCT00983164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Supplementation
Description: antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
Study NCT00517933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
Study NCT00517933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
Study NCT02971930 — intervention group
Intervention type: BIOLOGICAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027
Study NCT03523962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuraPrep
Description: The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
Study NCT03523962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep
Description: The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
Study NCT01022489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation: rTMS
Description: 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
Study NCT01022489 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sham coil) treatment
Description: Sham coil treatment
Study NCT02664194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus® Cooling System
Description: Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
Study NCT02664194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary percutaneous coronary intervention
Study NCT02664194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary percutaneous coronary intervention
Study NCT02955498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevikar tab. 10/40mg
Description: Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
Study NCT02955498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivikar tab. 5/40mg
Description: Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
Study NCT02979899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRC105
Description: TRC105 antibody
Study NCT02979899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Votrient
Description: pazopanib
Study NCT02979899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Votrient
Description: pazopanib
Study NCT02902172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Study NCT01253226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399 (Tabalumab)
Description: Administered subcutaneously
Study NCT01253226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT02499471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Levothyroxine therapy (137.75 ± 23.75 μg/day)
Description: This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: canakinumab-matching placebo
Description: canakinumab placebo every 3 weeks (squamous and non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pembrolizumab
Description: 200 mg every 3 weeks (squamous and non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 every 3 weeks (non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: 75 mg/m\^2 every 3 weeks (non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m\^2 every 3 weeks (squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Description: 200 mg/m\^2 every 3 weeks (squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 every 3 weeks (non-squamous)
Study NCT03631199 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed
Description: 500 mg/m\^2 every 3 weeks (non-squamous)
Study NCT01834144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Study NCT03342391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transnasal esophagoscopy
Description: single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
Study NCT01740440 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BMR Face
Description: BMR Face used in accordance with manufacturer IFU
Study NCT02426372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBECO SSI
Description: QBECO Site Specific Immunomodulators
Study NCT03065504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric
Study NCT03065504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric-containing combination tablet
Study NCT03065504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT02825264 — intervention group
Intervention type: DEVICE
Intervention: STARflo Implant
Description: All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
Study NCT04322630 — intervention group
Intervention type: OTHER
Intervention: Change in Soluble MER Concentration
Description: Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
Study NCT03584490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Administration of Questionnaires
Description: This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
Study NCT03584490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone Administration of Questionnaires
Description: This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
Study NCT03870100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous
Study NCT02418429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waxy maize starch
Description: pancake test meal with waxy maize starch only
Study NCT02418429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waxy maize starch and Whey Protein
Description: pancake test meal with waxy maize starch and whey protein
Study NCT02418429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: pancake test meal with resistant starch only
Study NCT02418429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistant starch and whey protein
Description: pancake test meal with resistant starch and whey protein
Study NCT00647894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-Release Tablets 1 mg
Study NCT03300284 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Quality of Life Questionnaires
Study NCT03474861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anticancer medication A01; immune cells IC01
Description: The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
Study NCT04382300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib combined with thalidomide
Description: Single Group Assignment
Study NCT02391701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
Study NCT02835742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Study NCT02835742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04711434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: Toripalimab: 240mg IV every 3 months for a year
Study NCT04525352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L401
Description: CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
Study NCT05614232 — intervention group
Intervention type: RADIATION
Intervention: Chest X-ray
Description: Chest radiographs
Study NCT00647894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax XR Tablets 1 mg
Study NCT02910024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol
Description: iTBS applied over ipsilesional M1
Study NCT01195246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Description: Intramuscular (IM) injection on Day1
Study NCT01195246 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injection on Day 1
Study NCT01195246 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix
Description: Intramuscular (IM) injection on Day 1
Study NCT03459170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 T cells
Description: Biological: T cells transduced with CaspaCIDe® safety switch
Study NCT03459170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimiducid
Description: administered to eliminate BPX-501 cells in the event of GVHD
Study NCT03385200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SonoVue
Description: As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
Study NCT04465071 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AEONTM Repair and AEONTM Protect Plus lubricating eye drops
Description: AEONTM Repair and AEONTM Protect Plus lubricating eye drops
Study NCT02707107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusions of WCK 5222
Study NCT02707107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01813188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ABM seeded onto a porous TCP and DBM
Description: cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)
Study NCT01582945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
Study NCT01813188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone graft
Description: autologous bone graft
Study NCT02910024 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Super Rapid2 System, sham-stimulation (in iTBS)
Description: iTBS applied with tilted coil over parieto-occipital vertex
Study NCT02025322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors.
Study NCT01545674 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from the mother and father